Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kara Gibson

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|March 20, 2009
Tetanus in developing countries: a case series and reviewKara Gibson, J Bonaventure Uwineza, Willy Kiviri, et al.
Eye (London, England)|July 29, 2024
INFOGRAPHIC: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from YOSEMITE and RHINE)Naomi Wijesingha, Kara Gibson, Jeffrey R Willis, et al.
Ophthalmology and Therapy|June 18, 2026
Summary of Research: Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension TrialVeeral S Sheth, Stela Vujosevic, Alex Kotak, et al.
The Canadian Journal of Cardiology|July 10, 2008
Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepinesAdrian Baranchuk, Christopher S Simpson, Michelle Methot, et al.
Ophthalmology and Therapy|September 19, 2025
Does the Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema in Randomized Trials Translate into Real-World Settings?Tunde Peto, Stela Vujosevic, Veeral Sheth, et al.
Ophthalmology and Therapy|May 17, 2017
Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRAYit Yang, Louise Downey, Hemal Mehta, et al.
Ophthalmology. Retina|May 29, 2025
Treatment Patterns and Long-term Outcomes with Anti-VEGF Therapy for Retinal Vein Occlusion: An Analysis of the Vestrum DatabaseMichael Ip, Yasha Modi, Sharon Fekrat, et al.
Retina (Philadelphia, Pa.)|July 16, 2025
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALSGlenn J Jaffe, Gábor Deák, Kara Gibson, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|December 21, 2024
Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseasesVarun Chaudhary, Florie Mar, Manuel J Amador, et al.
Ophthalmic Research|May 15, 2026
A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular EdemaJennifer I Lim, Theodore Leng, Jakob Siedlecki, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|March 20, 2009
Tetanus in developing countries: a case series and reviewKara Gibson, J Bonaventure Uwineza, Willy Kiviri, et al.
Eye (London, England)|July 29, 2024
INFOGRAPHIC: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from YOSEMITE and RHINE)Naomi Wijesingha, Kara Gibson, Jeffrey R Willis, et al.
Ophthalmology and Therapy|June 18, 2026
Summary of Research: Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension TrialVeeral S Sheth, Stela Vujosevic, Alex Kotak, et al.
The Canadian Journal of Cardiology|July 10, 2008
Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepinesAdrian Baranchuk, Christopher S Simpson, Michelle Methot, et al.
Ophthalmology and Therapy|September 19, 2025
Does the Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema in Randomized Trials Translate into Real-World Settings?Tunde Peto, Stela Vujosevic, Veeral Sheth, et al.
Ophthalmology and Therapy|May 17, 2017
Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRAYit Yang, Louise Downey, Hemal Mehta, et al.
Ophthalmology. Retina|May 29, 2025
Treatment Patterns and Long-term Outcomes with Anti-VEGF Therapy for Retinal Vein Occlusion: An Analysis of the Vestrum DatabaseMichael Ip, Yasha Modi, Sharon Fekrat, et al.
Retina (Philadelphia, Pa.)|July 16, 2025
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALSGlenn J Jaffe, Gábor Deák, Kara Gibson, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|December 21, 2024
Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseasesVarun Chaudhary, Florie Mar, Manuel J Amador, et al.
Ophthalmic Research|May 15, 2026
A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular EdemaJennifer I Lim, Theodore Leng, Jakob Siedlecki, et al.
Pageof 2